Tedisamil attenuates foetal transformation of myosin in the hypertrophied rat myocardium

British Journal of Pharmacology

Volumn 143, Issue 5, 2004, Pages 561-572

  Turcani, Marian ^a   Thormaehlen, Dirk ^b   Rupp, Heinz ^c  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Solvay Pharmaceuticals GmbH   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Heart hypertrophy; Myocardial contractility; Myosin isoforms; Potassium channel inhibition; Pressure overload; Tedisamil; Ventricular performance

Indexed keywords

CARDIAC MYOSIN; POTASSIUM CHANNEL; TEDISAMIL;

ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FETUS; HEART DEVELOPMENT; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE PRESSURE; HEART WEIGHT; MALE; NONHUMAN; PHENOTYPE; POSTNATAL DEVELOPMENT; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD PRESSURE; BODY WEIGHT; CARDIOMEGALY; CARDIOTONIC AGENTS; COLLAGEN; CYCLOPROPANES; ELECTROCARDIOGRAPHY; FETUS; FIBROSIS; HEART RATE; HYDROXYPROLINE; ISOENZYMES; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOSINS; ORGAN SIZE; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT;

EID: 8744249916     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705992     Document Type: Article

References (53)

1. BARGER, P.M., BRANDT, J.M., LEONE, T.C., WEINHEIMER, C.J. & KELLY, O.P. (2000). Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest., 105, 1723-1730.
2. BARRY, D.M., XU, H., SCHUESSLER, R.B. & NERBONNE, J.M. (1998). Functional knockout of the transient outward current, long-QT syndrome, and cardiac remodeling in mice expressing a dominant-negative Kv4 alpha subunit. Circ. Res., 83, 560-567.
3. + current blocker. Br. J. Pharmacol., 102, 13-18.
4. BROOKS, W.W., BING, O.H., CONRAD, C.H., O'NEILL, L., CROW, M.T., LAKATTA, E.G., DOSTAL, D.E., BAKER, K.M. & BOLUYT, M.O. (1997). Captopril modifies gene expression in hypertrophied and failing hearts of aged spontaneously hypertensive rats. Hypertension. 30, 1362-1368.
5. BUSCHMANN, G., SCHUMACHER, W., BUDDEN, R. & KÜHL, U.G. (1980). Evaluation of the effect of dopamine and other catecholamines on the electrocardiogram and blood pressure of rats by means of on-line biosignal processing. J. Cardiovasc. Pharmacol., 2, 777-795.
6. CHI, L., PARK, J.L., FRIEDRICHS, G.S., BANGLAWALA, Y.A., FEREZ, M.A., TANHEHCO, E.J. & LUCCHESI, B.R. (1996). Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br. J. Pharmacol., 117, 1261-1269.
7. DEMOLIS, J.L., MARTEL, C., FUNCK-BRENTANO, C., SACHSE, A., WEIMANN, H.J. & JAILLON, P. (1997). Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br. J. Clin. Pharmacol., 4, 403-409.
8. DOGGRELL, S.A. & NAND, V. (2001). Effects of tedisamil on cardiovascular tissues isolated from normo- and hypertensive rats. J. Cardiovasc. Pharmacol. Ther., 6, 261-272.
9. DOGGRELL, S.A. (2001). Tedisamil: master switch of nature? Expert Opin. Invest. Drugs, 10, 129-138.
10. + currents in mammalian cardiac and glial cells. J. Pharmacol. Exp. Ther., 254, 560-569.
11. FOX, K.M., HENDERSON, J.R., KASKI, J.C., SACHSE, A., KUESTER, L. & WONNACOTT, S. (2000). Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart, 83, 167-171.
12. FRIEDRICHS, G.S., ABREU, J.N., COUSINS, G.R., CHI, L., BORLAK, J. & LUCCHESI, B.R. (1996). Tedisamil attenuates ventricular fibrillation in a conscious canine model of sudden cardiac death. J. Cardiovasc. Pharmacol. Ther., 4, 313-324.
13. GULCH, R.W. (1980). The effect of elevated chronic loading on the action potential of mammalian myocardium. J. Mol. Cell. Cardiol., 12, 415-420.
14. HANSEN, M. & RUPP, H. (1994). Mismatch between sinus node activity and ventricular organelle function ('sinus node mismatch' - pathogenesis and novel therapeutic approaches). The Adapted Heart, Nagano, M., Takeda, N. & Dhalla, N.S. (eds). New York: Raven Press, pp. 321-342.
15. HERRON, T.J. & MCDONALD, K.S. (2002). Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ. Res., 90, 1150-1152.
16. HERRON, T.J., KORTE, F.S. & MCDONALD, K.S. (2001). Loaded shortening and power output in cardiac myocytes are dependent on myosin heavy chain isoform expression. Am. J. Physiol Heart Circ. Physiol., 281, H1217-H1222.
17. 2+]; in rat ventricular myocytes following myocardial infarction. J. Physiol., 517 (Part 1), 229-245.
18. KASSIRI, Z., ZOBEL, C., NGUYEN, T.T., MOLKENTIN, J.D. & BACKX, P.H. (2002). Reduction of I(to) causes hypertrophy in neonatal rat ventricular myocytes. Circ. Res., 90, 578-585.
19. KATZ, A.M. (1989). Changing strategies in the management of heart failure. J. Am. Coll. Cardiol., 13, 513-523.
20. KOBINGER, W. (1985). Specific bradycardic agents, a new approach to therapy in angina pectoris. Prog. Pharmacol., 5/4, 89-100.
21. KUO, H.C., CHENG, C.F., CLARK, R.B., LIN, J.J., LIN, J.L., HOSHIJIMA, M., NGUYEN-TRAN, V.T., GU, Y., IKEDA, Y., CHU, P.H., ROSS, J., GILES, W.R. & CHIEN, K.R. (2001). A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia. Cell, 14, 801-813.
22. LI, M., ZHENG, C, SATO, T., KAWADA, T., SUGIMACHI, M. & SUNAGAWA, K. (2004). Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation, 109, 120-124.
23. LITWIN, S.E., KATZ, S.E., WEINBERG, E.O., LORELL, B.H., AURIGEMMA, G.P. & DOUGLAS, P.S. (1995). Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation, 15, 2642-2654.
24. LOWES, B.D., GILBERT, E.M., ABRAHAM, W.T., MINOBE, W.A., LARRABEE, P., FERGUSON, D., WOLFEL, E.E., LINDENFELD, J., TSVETKOVA, T., ROBERTSON, A.D., QUAIFE, R.A. & BRISTOW, M.R. (2002). Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med., 346, 1357-1365.
25. MICHELAKIS, E.D., MCMURTRY, M.S., WU, X.C., DYCK, J.R., MOUDGIL, R., HOPKINS, T.A., LOPASCHUK, G.D., PUTTAGUNTA, ?tlsb>L., WAITE, R. & ARCHER, S.L. (2002). Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation, 105, 244-250.
26. MIRSKY, I. & PARMLEY, W.W. (1973). Assessment of passive elastic stiffness for isolated heart muscle and the intact heart. Circ. Res., 33, 233-243.
27. MOLKENTIN, J.D., LU, J.R., SANTOS, C.L., MARKHAM, B., RICHARDSON, J., ROBBINS, J., GRANT, S.R. & OLSON, E.N. (1998). A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell, 93, 215-228.
28. NADOR, F., BERIA, G., DE FERRARI, G.M., STRAMBA-BADIALE, M., LOCATI, E.H., LOTTO, A. & SCHWARTZ, P.J. (1991). Unsuspected echocardiographic abnormality in the long QT syndrome. Diagnostic, prognostic, and pathogenetic implications. Circulation, 84, 1530-1542.
29. PATERNOSTRO, G., PAGANO, D., GNECCHI-RUSCONE, T., BONSER, R.S. & CAMICI, P.G. (1999). Insulin resistance in patients with cardiac hypertrophy. Cardiovasc. Res., 42, 246-253.
30. RUPP, H. & JACOB, R. (1992). Metabolically-modulated growth and phenotype of the rat heart. Eur. Heart J., 13 (Suppl D), 56-61.
31. RUPP, H., WAHL, R. & HANSEN, M. (1992). Influence of diet and carnitine palmitoyltransferase I inhibition on myosin sarcoplasmic reticulum. J. Appl. Physiol., 72, 352-360.
32. SABBAH, H.N., SHAROV, V.G., GUPTA, R.C., MISHRA, S., RASTOGI, S., UNDROVINAS, A.I., CHAUDHRY, P.A., TODOR, A., MISHIMA, T., TANHEHCO, E.J. & SUZUKI, G. (2003). Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ. Res., 28, 1095-1101.
33. 2+ influx protects cardiac morphology and ventricular function in K(v)4.2N transgenic mice. Circulation, 105, 1850-1856.
34. SAH, R., RAMIREZ, R.J., OUDIT, G.Y., GIDREWICZ, D., TRIVIERI, M.G., ZOBEL, C. & BACKX, P.H. (2003). Regulation of cardiac excitation-contraction coupling by action potential repolarization: role of the transient outward potassium current (I(to)). J. Physiol., 546 (Part 1), 5-18.
35. SAMBANDAM, N., LOPASCHUK, G.D., BROWNSEY, R.W. & ALLARD, M.F. (2002). Energy metabolism in the hypertrophied heart. Heart Fail. Rev., 1, 161-173.
36. SANDLER, H. & DODGE, H.T. (1963). Left ventricular tension and stress in man. Circ. Res., 3, 91-104.
37. + current and cardiac hypertrophy: causal relationship or epiphenomenon? Circ. Res., 90, 497-499.
38. SCHWARTZ, K., BOUVERET, P., BERCOVICI, J. & SWYNGHEDAUW, B. (1978). An immunochemical difference between myosins from normal and hypertrophied rat hearts. FEBS Lett., 93, 137-140.
39. SEIPEL, L. & HOFFMEISTER, H.M. (1989). Hemodynamic effects of antiarrhythmic drugs: negative inotropy versus influence on peripheral circulation. Am. J. Cardiol., 64, J37-J40.
40. SEKI, S., TRIBULOVA, N., MANOACH, M. & MOCHIZUKI, S. (2003). Modulation of intracellular Ca(2+) concentration by tedisamil, a class III antiarrhythmic agent, in isolated heart preparation. Life Sci., 73, 1805-1811.
41. STEGEMANN, H. & STALDER, K. (1967). Determination of hydroxyproline. Clin. Chim. Acta, 18, 267-273.
42. SWYNGHEDAUW, B., BAILLARD, C. & MILLIEZ, P. (2003). The long QT interval is not only inherited but is also linked to cardiac hypertrophy. J. Mol. Med., 81, 336-345.
43. THORMANN, J., MITROVIC, V., RIEDEL, H., NEUZNER, J., STRASSER, R., BAHAVAR, H. & SCHLEPPER, M. (1993). Tedisamil (KC 8857) is a new specific bradycardic drug: does it also influence myocardial contractility? Analysis by the conductance (volume) technique in coronary artery disease. Am. Heart J., 125 (Part 1), 1233-1246.
44. TURCANI, M. & RUPP, H. (1997). Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation, 96, 3681-3686.
45. TURCANI, M. & RUPP, H. (2000). Bradykinin (B2) independent effect of captopril on the development of pressure overload cardiac hypertrophy. Mol. Cell. Biochem., 212, 219-225.
46. VERDUYN, S.C., RAMAKERS, C., SNOEP, G., LEUNISSEN, J.D., WELLENS, H.J. & VOS, M.A. (2001). Time course of structural adaptations in chronic AV block dogs: evidence for differential ventricular remodeling. Am. J. Physiol. Heart Circ. Physiol., 280, H2882-H2890.
47. WALLACE, A.A., STUPIENSKI, R.F., III BASKIN, E.P., APPLEBY, S.D., KOTHSTEIN, T., GEHRET, J.R., KING, S.W., REMY, D.C. & LYNCH JR, J.J. (1995). Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. J. Pharmacol. Exp. Ther., 273, 168-175.
48. WASADA, T., YANO, T., OHTA, M., YUI, N. & IWAMOTO, Y. (2001). ATP-sensitive potassium channels modulate glucose transport in cultured human skeletal muscle cells. Endocr. J., 48, 369-375.
49. WICKENDEN, A.D., LEE, P., SAH, R., HUANG, Q., FISHMAN, G.I. & BACKX, P.H. (1999). Targeted expression of a dominant-negative K(v)4.2 K(+) channel subunit in the mouse heart. Circ. Res., 85, 1067-1076.
50. YOUNG, M.E., LAWS, P.A., GOODWIN, G.W. & TAEGTMEYER, H. (2001). Reactivation of peroxisome proliferator-activated receptor α is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem., 276, 44390-44395.
51. ZARAIN-HERZBERG, A. & RUPP, H. (2002). Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin. Invest. Drugs, 11, 345-356.
52. ZHANG, T.T., TAKIMOTO, K., STEWART, A.F., ZHU, C. & LEVITAN, E.S. (2001). Independent regulation of cardiac Kv4.3 potassium channel expression by angiotensin II and phenylephrine. Circ. Res., 88, 476-482.
53. ZOBEL, C., KASSIRI, Z., NGUYEN, T.T., MENG, Y. & BACKX, P.H. (2002). Prevention of hypertrophy by overexpression of Kv4.2 in cultured neonatal cardiomyocytes. Circulation, 106, 2385-2391.